Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Dear Investors, 

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) has received approval to expand its Phase II Clinical Trial for treating Diabetic Foot Infections (DFI) with RECCE® 327 Topical Gel. This approval allows for up to 20 additional patients to access the treatment under the existing open-label study protocol. The study's focus on DFI is crucial due to the high recurrence rate of foot ulcers in diabetics, with a 40% recurrence rate within the first year of healing.

The recent Phase II data showed promising results, with R327G demonstrating a successful clinical response in a majority of patients. This study aims to further strengthen the clinical profile of R327G while addressing the urgent needs of patients lacking effective treatment options. Importantly, this initiative will run parallel to our Phase 3 trials in Indonesia and Australia, supporting our commitment to combat antimicrobial resistance and provide innovative treatment solutions.

Dear Investors, Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) has received approval to expand its Phase II Clinical Trial for treating Diabetic Foot Infections (DFI) with RECCE® 327 Topical Gel. This approval allows for up to 20 additional patients to access the treatment under the existing open-label study protocol. The study's focus on DFI is crucial due to the high recurrence rate of foot ulcers in diabetics, with a 40% recurrence rate within the first year of healing. The recent Phase II data showed promising results, with R327G demonstrating a successful clinical response in a majority of patients. This study aims to further strengthen the clinical profile of R327G while addressing the urgent needs of patients lacking effective treatment options. Importantly, this initiative will run parallel to our Phase 3 trials in Indonesia and Australia, supporting our commitment to combat antimicrobial resistance and provide innovative treatment solutions. We invite investors to engage with us and learn more about this significant development. Feel free to ask any questions or seek clarification on how this milestone aligns with our strategic growth objectives. Thank you for your continued support, [CEO Name] Chief Executive Officer Recce Pharmaceuticals Ltd.

Phase II Clinical Trial Receives Additional Approval for DFI

Summary